Drew Moghanaki: Outcomes for stage I NSCLC treated with minimally invasive surgery or SABR
Drew Moghanaki, Professor and Chief of Thoracic Oncology at the Department of Radiation Oncology at UCLA, shared a post on X about a paper by Julianne Cynthia de Ruiter et al. published in Lung Cancer:
Authors: Julianne Cynthia de Ruiter, Vincent van der Noort, Judi Nani Annet van Diessen, Egbert Frederik Smit, Ronald Alphons Maria Damhuis, Koen Johan Hartemink.
“The Dutch ESLUNG study is potentially the largest prospective registry (n=2,183) evaluating outcomes for stage I NSCLC treated with minimally invasive surgery or SABR. Their non-randomized data, when propensity-matched, show similar findings to those previously reported by the Revised STARS study with no measurable difference in OS.
The ESLUNG study used a propensity-matching model considering the usual baseline health factors that confound OS comparisons.
However, their PS model didn’t include pre-treatment staging by EBUS, which occurred in 21% of surgical and only 12% of SABR patients. From my perspective, this is a crucial unmeasured confounder that could’ve pinched together the relapse-free survival curves, suggesting upfront SABR patients need ‘more treatment’ than if they instead underwent upfront surgery.
For those unfamiliar with the Revised STARS study from MD Anderson, here’s a refresher and a URL to learn more about what happened to their prospective cohort of operable patients treated with SABR, when 90% of them were staged by EBUS.
Authors: Joe Chang et al.
I’m hopeful the ESLUNG study group, funded by the Dutch Cancer Society, will continue to publish from this rich prospective dataset. Their results will certainly help those of us who continue sorting when to feel comfortable endorsing surgery for patients with stage I NSCLC who can so easily be treated with SABR instead.”
More posts featuring Drew Moghanaki.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023